M&A - NIKA PHARMACEUTICALS, INC

Form Type: 10-K

Filing Date: 2025-03-31

Corporate Action: Merger

Type: New

Accession Number: 000182646625000030

Filing Summary: Nika Pharmaceuticals, Inc. presents its annual report for the fiscal year ended December 31, 2024, highlighting major developments in its business strategy, including a significant merger with Nika BioTechnology, Inc. Effective April 12, 2024, this merger allowed Nika Pharmaceuticals to expand its controlling interest in Nika Europe, Ltd. from 40% to 80%. The company executed the agreement by exchanging common and preferred stock. The document detailed various strategic partnerships aimed at the production and distribution of medical products, as well as significant financial challenges faced, such as an accumulated deficit of over $8.9 million and a net loss of nearly $96,000 for the fiscal year. Plans for future financing are under consideration, with management acknowledging the importance of additional funding for sustaining operations until profitability can be achieved. The report also addresses the risks associated with being an emerging growth company, educational details on their operations, directors, executive compensation, and financial statements for the year 2024.

Document Link: View Document